ArticleScientific reports2026
Dose-dependent effects of radiotherapy on body composition, nutritional status, and clinical symptoms in head and neck cancer.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Weight loss despite nutritional support predicts poor outcomes after postoperative chemoradiotherapy for high-risk head and neck cancer.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026Article
- Timing matters: gastrostomy placement and outcomes in patients with head and neck cancer undergoing chemoradiotherapy.Frontiers in nutrition · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Radiotherapy (RT) and chemoradiotherapy (CRT) for head and neck cancer (HNC) frequently result in significant malnutrition, muscle wasting, and systemic inflammation, which can compromise treatment tolerance and clinical outcomes. This study aimed to evaluate the dose-volume effects of RT, symptom burden, and treatment modality on nutritional status, body composition, and inflammatory markers in HNC patients. Eighty-five patients with HNC undergoing adjuvant or definitive RT/CRT were prospectively evaluated at baseline, at the end of treatment, and 6-12 weeks post-treatment. Nutritional status was assessed using the Patient-Generated Subjective Global Assessment (PG-SGA), anthropometric measurements, bioelectrical impedance analysis (BIA), handgrip strength, and laboratory parameters (albumin, prealbumin, transferrin, CRP, hemoglobin, and lymphocytes). Receiver operating characteristic (ROC) analyses were performed to identify RT dose-volume thresholds associated with clinically significant weight and muscle loss. The prevalence of malnutrition increased from 33.3% at baseline to 65.3% at the end of treatment and remained high at 55.6% during follow-up. 42% of patients experienced ≥ 4.6% weight loss, and 49% had ≥ 4.8% muscle mass loss. Higher RT doses (> 65 Gy), larger high-dose volumes (> 48 cc), and greater symptom burden were significantly associated with clinically relevant deterioration in body composition. Patients requiring nutritional support showed greater weight and muscle loss; however, this likely reflects confounding by indication, as these patients had more advanced disease and higher baseline symptom burden. CRP levels increased significantly during treatment, while hemoglobin and lymphocyte counts decreased. RT for head and neck cancer causes substantial and persistent deterioration in nutritional status, muscle mass, and inflammatory markers. RT dose-volume parameters and symptom burden are important predictors of nutritional decline. Early, individualized nutritional intervention combined with effective symptom management is essential to improve treatment outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.